Luoqi Biotech

Luoqi Biotech (洛启生物) is a Qiming Venture Partners portfolio company developing inhaled biologics, with its core product LQ036 — an inhaled single-domain antibody targeting IL-4Rα — aimed at respiratory disease. Per Qiming's own updates, LQ036 completed a Phase 2a proof-of-concept study in patients with moderate-to-severe asthma in early 2025 , and by August 2025 had advanced to a Phase 2b trial, with the lead-site kickoff held at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine . Elsewhere's corpus covers it only through these Qiming portfolio dispatches, so details like its founding, full pipeline, and financing history aren't documented here.